Table 1. FDA Approved immunotherapies for childhood cancers.

B-ALL: B-cell Acute lymphoblastic leukemia; HL: Hodgkin lymphoma; CRC: Colorectal Cancer

Identifier	Study name	Target	Phase	Disease (s)	Intervention (s)	Reference
NCT01471782	Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia	CD19	1/2	B-ALL	Blinatumomab, anti-CD19 BiTE	(von Stackelberg, et al., 2016)
NCT02435849	Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse.	CD19	2	B-ALL	Tisagenlecleucel (CTL019); CAR T cell	(Maude, et al., 2018)
NCT00026312	Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma	GD2	3	Localized/Regional Neuroblastoma Recurrent Neuroblastoma Stage 4/4S Neuroblastoma	Aldesleukin Dinutuximab Isotretinoin Sargramostim	(A. L. Yu, et al., 2010)
NCT02332668	A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475–051/KEYNOTE-051)	PD1	1/2	Melanoma Lymphoma Classical HL Microsatellite-instabilityhigh Solid Tumor	Pembrolizumab (MK-3475) Humanized IgG4 monoclonal antibody	(Geoerger, et al., 2020)
NCT02060188	An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread	PD1	2	Microsatellite Unstable/Stable CRC Mismatch Repair Proficient/Deficient CRC	Ipilimumab Nivolumab Cobimetinib Daratumumab anti-LAG-3 antibody	(Overman, et al., 2017)
NCT00094653	MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma	CTLA-4	3	Melanoma Metastases	MDX-010 (anti-CTLA4) monoclonal antibody MDX-1379 (gp100) Melanoma Peptide Vaccine	(Hodi, et al., 2010)